Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon

[1]  I. Melero,et al.  Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12. , 2015, Cancer research.

[2]  C. Heirman,et al.  mRNA-based dendritic cell vaccines , 2015, Expert review of vaccines.

[3]  C. Heirman,et al.  The ReNAissanCe of mRNA-based cancer therapy , 2015, Expert review of vaccines.

[4]  C. Heirman,et al.  Targeting the tumor microenvironment to enhance antitumor immune responses , 2014, Oncotarget.

[5]  R. Vandenbroucke,et al.  Choose your models wisely: how different murine bone marrow-derived dendritic cell protocols influence the success of nanoparticulate vaccines in vitro. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[6]  S. Smedt,et al.  Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment , 2014 .

[7]  C. Heirman,et al.  Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity , 2014, Oncotarget.

[8]  A. Galy,et al.  Immunization of Mice with Lentiviral Vectors Targeted to MHC Class II+ Cells Is Due to Preferential Transduction of Dendritic Cells In Vivo , 2014, PloS one.

[9]  K. Leong,et al.  Messenger RNA (mRNA) nanoparticle tumour vaccination. , 2014, Nanoscale.

[10]  K. Leong,et al.  Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity , 2014, Scientific Reports.

[11]  P. De Baetselier,et al.  Immunogenicity of targeted lentivectors , 2014, Oncotarget.

[12]  G. Schuler,et al.  CD8+ T-cell priming and boosting: more antigen-presenting DC, or more antigen per DC? , 2013, Cancer Immunology, Immunotherapy.

[13]  P. De Baetselier,et al.  Targeting of Human Antigen-Presenting Cell Subsets , 2013, Journal of Virology.

[14]  C. Mandl,et al.  RNA: the new revolution in nucleic acid vaccines. , 2013, Seminars in immunology.

[15]  C. Heirman,et al.  mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. , 2013, Human vaccines & immunotherapeutics.

[16]  G. Pantaleo,et al.  Functional Avidity: A Measure to Predict the Efficacy of Effector T Cells? , 2012, Clinical & developmental immunology.

[17]  R. Schreiber,et al.  Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. , 2012, Cell host & microbe.

[18]  C. Heirman,et al.  Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. , 2012, Cancer research.

[19]  P. De Baetselier,et al.  Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells , 2012, Gene Therapy.

[20]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[21]  Jason Z. Oh,et al.  TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. , 2011, Blood.

[22]  C. Pichon,et al.  Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[23]  Ö. Türeci,et al.  Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation , 2011, Gene Therapy.

[24]  K. Thielemans,et al.  mRNA: delivering an antitumor message? , 2011, Immunotherapy.

[25]  R. Germain,et al.  Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. , 2011, The Journal of clinical investigation.

[26]  Ana Rouzaut,et al.  Direct Effects of Type I Interferons on Cells of the Immune System , 2011, Clinical Cancer Research.

[27]  J. Rosenecker,et al.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice , 2011, Nature Biotechnology.

[28]  M. Fotin‐Mleczek,et al.  Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity , 2011, Journal of immunotherapy.

[29]  U. Şahin,et al.  Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. , 2010, Cancer research.

[30]  Gaurav Sahay,et al.  Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[31]  K. Karwacz,et al.  HIV-1 Lentiviral Vector Immunogenicity Is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7 , 2010, Journal of Virology.

[32]  K. Breckpot,et al.  Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. , 2009, Endocrine, metabolic & immune disorders drug targets.

[33]  C. G. Hansen,et al.  Molecular mechanisms of clathrin-independent endocytosis , 2009, Journal of Cell Science.

[34]  H. Rammensee,et al.  Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients , 2009, Journal of immunotherapy.

[35]  Feng Xu,et al.  In vitro macrophage uptake and in vivo biodistribution of PLA–PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content , 2009, Journal of materials science. Materials in medicine.

[36]  G. Caracciolo,et al.  Structural stability and increase in size rationalize the efficiency of lipoplexes in serum. , 2009, Langmuir : the ACS journal of surfaces and colloids.

[37]  Hiroki Kato,et al.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  Parag Aggarwal,et al.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.

[39]  Warren C W Chan,et al.  Nanoparticle-mediated cellular response is size-dependent. , 2008, Nature nanotechnology.

[40]  Marleen Keyaerts,et al.  Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of d-luciferin: effect on intensity, time kinetics and repeatability of photon emission , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  Shubiao Zhang,et al.  Lipoplex morphologies and their influences on transfection efficiency in gene delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[42]  I. Zuhorn,et al.  Gene delivery by cationic lipids: in and out of an endosome. , 2007, Biochemical Society transactions.

[43]  Gunther Hartmann,et al.  5'-Triphosphate RNA Is the Ligand for RIG-I , 2006, Science.

[44]  G. Molema,et al.  Transfection mediated by pH-sensitive sugar-based gemini surfactants; potential for in vivo gene therapy applications , 2006, Journal of Molecular Medicine.

[45]  N. Van Rooijen,et al.  Impact of macrophage and dendritic cell subset elimination on antiviral immunity, viral clearance and production of type 1 interferon. , 2005, Virology.

[46]  Houping Ni,et al.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. , 2005, Immunity.

[47]  D. Larkin,et al.  Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. , 2005, Blood.

[48]  Christophe Caux,et al.  A type I interferon autocrine–paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells , 2005, The Journal of experimental medicine.

[49]  H. Rammensee,et al.  Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA , 2005, European journal of immunology.

[50]  K. McCullough,et al.  Double‐stranded secondary structures on mRNA induce type I interferon (IFN α/β) production and maturation of mRNA‐transfected monocyte‐derived dendritic cells , 2005, The journal of gene medicine.

[51]  D. Weissman,et al.  mRNA Is an Endogenous Ligand for Toll-like Receptor 3* , 2004, Journal of Biological Chemistry.

[52]  Y. Barenholz,et al.  The Role of Organ Vascularization and Lipoplex-Serum Initial Contact in Intravenous Murine Lipofection* , 2003, Journal of Biological Chemistry.

[53]  H. Merkle,et al.  Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. , 2003, Biomaterials.

[54]  Sandra L. Schmid,et al.  Regulated portals of entry into the cell , 2003, Nature.

[55]  Christine A. Biron,et al.  Coordinated and Distinct Roles for IFN-αβ, IL-12, and IL-15 Regulation of NK Cell Responses to Viral Infection1 , 2002, The Journal of Immunology.

[56]  G. Linette,et al.  Antimelanoma Activity of CTL Generated from Peripheral Blood Mononuclear Cells After Stimulation with Autologous Dendritic Cells Pulsed with Melanoma gp100 Peptide G209-2M Is Correlated to TCR Avidity , 2002, The Journal of Immunology.

[57]  P. Rod Dunbar,et al.  Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols1 , 2002, The Journal of Immunology.

[58]  G. Trinchieri,et al.  Type I interferons and IL‐12: convergence and cross‐regulation among mediators of cellular immunity , 2001, European journal of immunology.

[59]  Y. Kaneda,et al.  RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. , 1999, Human gene therapy.

[60]  S. Rosenberg,et al.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. , 1999, Journal of immunology.

[61]  J. Sprent,et al.  Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. , 1998, Immunity.

[62]  F. Szoka,et al.  Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. , 1998, Biochimica et biophysica acta.

[63]  Leaf Huang,et al.  Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA , 1997, Gene Therapy.

[64]  G. Lenzen,et al.  Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA , 1993, European journal of immunology.

[65]  Stefaan C De Smedt,et al.  Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger. , 2016, Drug discovery today.

[66]  G. Vanham,et al.  Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  S. Pascolo.  Vaccination with messenger RNA (mRNA). , 2008, Handbook of experimental pharmacology.

[68]  C. Biron,et al.  Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. , 2000, Nature immunology.